Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
O75844
UPID:
FACE1_HUMAN
Alternative names:
Farnesylated proteins-converting enzyme 1; Prenyl protein-specific endoprotease 1; Zinc metalloproteinase Ste24 homolog
Alternative UPACC:
O75844; B3KQI7; D3DPU7; Q8NDZ8; Q9UBQ2
Background:
CAAX prenyl protease 1 homolog, also known as Farnesylated proteins-converting enzyme 1, plays a pivotal role in cellular processes by processing lamin A/LMNA and clearing translocons on the endoplasmic reticulum. Its proteolytic activity is essential for the removal of C-terminal residues of farnesylated proteins, impacting various cellular mechanisms.
Therapeutic significance:
Linked to diseases such as Mandibuloacral dysplasia with type B lipodystrophy and Restrictive dermopathy 1, CAAX prenyl protease 1 homolog's understanding could pave the way for novel therapeutic approaches targeting these rare but severe conditions.